Remifentanil prevents increases of blood glucose and lactate during cardiopulmonary bypass in pediatric cardiac surgery

Remifentanil prevents increases of blood glucose and lactate during cardiopulmonary bypass in pediatric cardiac surgery - Remifentanil prevents blood glucose and lactate elevations during pediatric CPB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025139

Enrollment

Registered

2016-12-05

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: children received atrial or ventricular septal defect repair under cardiopulmonary bypass

Exclusion criteria

Exclusion criteria: children with glucose tolerance abnormality or hyperlactatemia

Design outcomes

Primary

Measure	Time frame
Blood glucose and lactate levels just before and after cardiopulmonary bypass	—

Countries

Japan

Contacts

Public ContactTomohiro Chaki

Sapporo Medical University School of Medicine Department of Anesthesiology

chakitomohiro0728@yahoo.co.jp011-611-2111

Outcome results